Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development

MIMETAS’ unique organ-on-a-chip and human tissue models complement Bruker’s multiomics, NMR, spatial biology and preclinical imaging solutions

Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker’s post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human physiology-relevant model systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810455540/en/ MIMETAS provides scalable organ-on-a-chip solutions for culturing and analyzing human-relevant tissues in a high-throughput plate format. The OrganoPlate® platform enables advanced disease modeling, drug testing, and safety assessment. Shown clockwise from the bottom right: immune cell migration from a blood vessel, a vascularized liver model, a gut tubule, a colon organoid-derived tubule, and a vascularized lung model